Centro de Oncología de Precisión - Santiago de Chile
Centro de Oncología de Precisión - Santiago de Chile
Santiago, Región Metropolitana de Santiago, 7560908
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Alejandro Poli
Marcelo Garrido Salvo
Open studies
Lung cancer
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) - MK-1084-004 - KANDLELIT-004 - Merck Sharp & Dohme LLCSee more
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) - MK-3475-01J/KEYMAKER-U01J - Merck Sharp & Dohme LLCSee more
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC - ALKAZAR - Nuvalent Inc.See more
Colorectal cancer
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) - MK-1084-012/KANDLELIT-012 - Merck Sharp & Dohme LLCSee more
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) - MK-1084-012/KANDLELIT-012 - Merck Sharp & Dohme LLCSee more
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation - CodeBreaK 301 - AmgenSee more
Breast Cancer
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) - HERTHENA-Breast04 - Merck Sharp & Dohme LLCSee more
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) - PionERA - Hoffmann-La RocheSee more
Gastrointestinal Cancer
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen - CAREFNDR - Crinetics Pharmaceuticals Inc.See more
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02) - MK-1022-011 - Merck Sharp & Dohme LLCSee more
Malignant neoplasm
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) - MK-3475-01J/KEYMAKER-U01J - Merck Sharp & Dohme LLCSee more
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) - KANDLELIT-014 - Merck Sharp & Dohme LLCSee more
Gastroesophageal cancer
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer - HLX22-GC-301 - Shanghai Henlius BiotechSee more
Carcinoid Syndrome
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen - CAREFNDR - Crinetics Pharmaceuticals Inc.See more
Pancreatic cancer
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen - CAREFNDR - Crinetics Pharmaceuticals Inc.See more
Liver cancer
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen - CAREFNDR - Crinetics Pharmaceuticals Inc.See more
Solid tumors
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) - KANDLELIT-014 - Merck Sharp & Dohme LLCSee more
Prostate cancer
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) - MK-2400-01A/IDeate-Prostate02 - Merck Sharp & Dohme LLCSee more
